Doximity, Inc. (DOCS) – What Are Investment Firms Thinking About This Stock?

Shares of Doximity, Inc. (NYSE:DOCS – Get Free Report) have received a consensus rating of “Hold” from the twenty-five analysts that are presently covering the firm, MarketBeat reports. Three equities research analysts have rated the stock with a sell recommendation, fourteen have issued a hold recommendation and eight have issued a buy recommendation on the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $30.45.

Several analysts recently issued reports on DOCS shares. JPMorgan Chase & Co. raised their target price on Doximity from $26.00 to $31.00 and gave the stock a “neutral” rating in a research note on Friday, August 7th. BMO Capital Markets reaffirmed a “market perform” rating and issued a $30.00 price target on shares of Doximity in a research note on Friday, August 7th. Stifel Nicolaus set a $27.00 price target on shares of Doximity in a report on Tuesday, September 8th. Raymond James Financial restated an “outperform” rating and issued a $38.00 price objective on shares of Doximity in a report on Friday, October 16th. Finally, Freedom Capital cut Doximity from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 8th.

Get Our Latest Research Report on DOCS

Doximity Price Performance

DOCS opened at $32.45 on Friday. The stock’s 50 day simple moving average is $29.33 and its 200 day simple moving average is $25.43. The firm has a market cap of $5.78 billion, a price-to-earnings ratio of 42.69, a PEG ratio of 34.25 and a beta of 1.29. Doximity has a 1 year low of $17.15 and a 1 year high of $54.04.

Doximity (NYSE:DOCS – Get Free Report) last released its quarterly earnings data on Thursday, November 5th. The company reported $0.36 earnings per share for the quarter, beating analysts’ consensus estimates of $0.19 by $0.17. The firm had revenue of $174.54 million during the quarter. Doximity had a return on equity of 15.80% and a net margin of 21.12%. The business’s revenue for the quarter was up 3.6% compared to the same quarter last year. During the same period last year, the company posted $0.45 EPS. As a group, sell-side analysts anticipate that Doximity will post 0.74 EPS for the current year.

Doximity News Roundup

Here are the key news stories impacting Doximity this week:

  • Positive Sentiment: Some analysts have raised Doximity’s price targets, including Canaccord Genuity to $40, and Needham reiterated its Buy rating. A recent report also highlighted adoption of Doximity’s AI search products by 16 of the top 20 pharmaceutical companies and 34% year-over-year growth in quarterly active workflow prescribers. Analyst price target report Doximity long-term investor takeaways
  • Neutral Sentiment: Director Timothy Cabral sold 10,721 shares for about $375,000. The transaction was made under a pre-arranged Rule 10b5-1 plan, which may make it less informative as a signal about his current outlook. Insider transaction report
  • Negative Sentiment: Multiple law firms publicized a securities class action covering shares purchased from August 8, 2024, through May 13, 2026, with a November 16 deadline to seek lead-plaintiff status. The complaint alleges Doximity misled investors about market-share losses, competition and advertising practices, including reliance on lower-engagement formats, as well as revenue and growth trends. These claims have not been proven, but the litigation adds uncertainty and could weigh on sentiment. Class action allegations and deadline Advertising disclosure allegations

Insider Transactions at Doximity

In related news, CAO Siddharth Sitaram sold 2,613 shares of the company’s stock in a transaction on Wednesday, October 14th. The stock was sold at an average price of $30.68, for a total value of $80,166.84. Following the sale, the chief accounting officer directly owned 101,432 shares of the company’s stock, valued at $3,111,933.76. This represents a 2.51% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Kira Wampler sold 2,000 shares of the company’s stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $32.89, for a total value of $65,780.00. Following the completion of the sale, the director directly owned 27,923 shares in the company, valued at approximately $918,387.47. The trade was a 6.68% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 24,471 shares of company stock worth $761,545. 31.80% of the stock is owned by company insiders.

Institutional Investors Weigh In On Doximity

Several large investors have recently bought and sold shares of DOCS. Carmignac Gestion increased its holdings in Doximity by 127.8% in the 1st quarter. Carmignac Gestion now owns 4,311,997 shares of the company’s stock worth $100,480,000 after acquiring an additional 2,418,971 shares in the last quarter. Renaissance Technologies LLC grew its holdings in Doximity by 29.4% during the 1st quarter. Renaissance Technologies LLC now owns 3,059,749 shares of the company’s stock valued at $71,292,000 after purchasing an additional 694,300 shares during the last quarter. Wellington Management Group LLP increased its stake in Doximity by 24.7% in the second quarter. Wellington Management Group LLP now owns 3,135,113 shares of the company’s stock worth $65,022,000 after purchasing an additional 621,464 shares during the period. Assenagon Asset Management S.A. purchased a new stake in shares of Doximity in the third quarter valued at approximately $28,858,000. Finally, Bank of America Corp DE grew its position in shares of Doximity by 31.8% during the 1st quarter. Bank of America Corp DE now owns 1,142,530 shares of the company’s stock worth $26,621,000 after buying an additional 275,650 shares in the last quarter. 87.19% of the stock is currently owned by institutional investors.

About Doximity

(Get Free Report)

Doximity, Inc. operates a digital platform designed for medical professionals, including physicians and other clinicians. Its services support professional networking, medical news and research discovery, career development, and communication among healthcare professionals. The company also offers clinical workflow tools, including Doximity Dialer, which enables clinicians to make calls and conduct video visits using a work number, as well as digital fax and document services. Doximity provides marketing and recruitment solutions to healthcare organizations and life sciences companies.

Further Reading

Analyst Recommendations for Doximity (NYSE:DOCS)

Receive News & Ratings for Doximity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Doximity and related companies with MarketBeat.com's FREE daily email newsletter.